NCT06182384View on ClinicalTrials.gov

A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

December 24, 2023

Primary Completion Date

May 13, 2024

Study Completion Date

May 13, 2024

Conditions
Moderate-to-Severe Plaque Psoriasis
Interventions
DRUG

SHR-1314

Receive a single dose of 240mg SHR-1314 at every period (First period：1mL AI, injection two needles. Second period: 2mL AI, injection one needle).

DRUG

SHR-1314

Receive a single dose of 240mg SHR-1314 at every period (First period：2mL AI, injection one needle. Second period: 1mL AI, injection two needles).

Trial Locations (1)

300041

The Second Hospital of Anhui Medical University, Hefei

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT06182384 - A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices | Biotech Hunter | Biotech Hunter